HC Wainwright & Co. Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $80
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Beam Therapeutics with a Buy rating and set a price target of $80.
July 23, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Beam Therapeutics with a Buy rating and set a price target of $80.
The initiation of coverage with a Buy rating and a price target of $80 by HC Wainwright & Co. is likely to positively impact Beam Therapeutics' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100